- Business：
- Language：
- ChineseEnglish
- Number： (86-21)52341008
- National Toll Free：400-700-3900
- E-mail：wangzhong@king-capital.com
- Office：Shanghai
- Business：
- Language：
- ChineseEnglish
- Number： (86-21)52341008
-
400-700-3900
- E-mail：wangzhong@king-capital.com
- Office：Shanghai
Since beginning legal practice, Wang Zhong has accumulated extensive practical experience in mergers and acquisitions, real estate, banking and insurance. He has expertise in M&A, and acts as independent director or supervisor for a number of leading companies. His advice is much sought-after by financial and investment companies and organisations.
Wang took part in the GATT (now WTO) senior lawyer and senior notary training held by the Chinese Ministry of Justice in 1993. He qualified as independent director through certification training held by the China Securities Regulatory Commission and Fudan University in 2002. He participated in the Central Party School Senior Seminar in 2006, the Advanced Venture Capital training of Shanghai Jiaotong University in 2008-2009, and the advanced international financial investment training of Shanghai Jiaotong University in 2010-2011, and participated in the study of civil and Commercial Law in New York University Law School in 2018, the exchange and training of legal talents between Hong Kong and Shanghai of The Hong Kong Institute of Finance and Management in 2018.
Mr. Wang is a partner of Beijing King and Capital and the director of our Shanghai Office. He is a member of the Chinese Law Society commissioner of the Criminal Law Committee of the ACLA (All-China Lawyers Association) and a member of the Shanghai Overseas Chinese Chamber of Commerce. He acts as independent director or supervisor of numerous famous companies.
Finance:
- China Hi-Tech (600730.SH) application to China Securities Regulatory Commission for issue of corporate bonds;
- Issue of medium-term notes in the inter-bank securities market by Shanghai Environmental Group Co., Ltd. and VV Food & Beverage Co., Ltd.;
- Shanghai Hai Fu and IDG, private finance totalling RMB 80 million yuan;
- Singapore Yingtai Biological Technology Co., Ltd overseas private finance totalling US $20 million.
Mergers and Acquisitions:
- Shanghai Zhicheng Biological Technology Co., Ltd. and Thermo Fisher Scientific Co., Ltd. equity merger and acquisition;
- Domestic strategic investments and mergers and acquisitions projects for Shanghai Ri-star Group Co., Ltd.;
- Japan Mitsui takeover of a Chinese-funded company’s shares;
- Hong Kong Gene Group restructuring;
- Equity M & A Projects of Shanghai Diary Group;
- Shanghai Wanxiang Cooling Equipment Co.,Ltd. restructuring and private financing;
- Singapore-listed Jishan Group takeover of a domestic company’s shares;
- Shanghai Shanxin Real Estate & Development Co., Ltd taking over Shanghai Precision & Scientific Instrument Co., Ltd.
Banking and Insurance:
- Debts restructuring and clean-up of Shanghai Pudong Development Bank;
- Preparation and the establishment of Sino Life Insurance Co., Ltd.;
- Pacific Investment Holdings Limited domestic asset restructuring;
- China Pacific Insurance (Group) Co., Ltd. overseas equity investment.
Capital Market:
- Shanghai Hi-Tech restructuring and listing;
- Shanghai Zhicheng Biological Technology Co., Ltd. restructuring and listing.
Real Estates:
- China Orient Asset Management Corporation real estate debt investment projects;
- Real estate development and operation project of Shanghai Nanjie Real Estate Development Co., Ltd., La Muralla Long S.L.
Dispute Resolution:
- Germany SAP copyright infringement case;
- Misappropriation of treasury bonds case involving a security company amounting to 410 million yuan.
